Prevalence of cognitive impairment in patients with substance use disorder.
Carolien J W H BruijnenBoukje A G DijkstraSerge J W WalvoortWiebren MarkusJoanneke E L VanDerNagelRoy P C KesselsCornelis A J De JongPublished in: Drug and alcohol review (2019)
Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance.